233 related articles for article (PubMed ID: 12675020)
1. Serogroup C meningococcal conjugate vaccines: new preparations. Effective from age two months.
Prescrire Int; 2003 Apr; 12(64):43-6. PubMed ID: 12675020
[TBL] [Abstract][Full Text] [Related]
2. Meningococcal B vaccine: new drug. The only vaccine against some serogroup B meningococci.
Prescrire Int; 2008 Jun; 17(95):95-7. PubMed ID: 18623907
[TBL] [Abstract][Full Text] [Related]
3. Meningococcal vaccine against serogroups A, C, Y and W-135: new preparation. Encouraging immunogenicity studies.
Prescrire Int; 2002 Apr; 11(58):35-8. PubMed ID: 11987309
[TBL] [Abstract][Full Text] [Related]
4. Meningococcal C vaccines: the Canadian experience.
De Wals P
Pediatr Infect Dis J; 2004 Dec; 23(12 Suppl):S280-4. PubMed ID: 15597070
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines.
Wysocki J; Tejedor JC; Grunert D; Konior R; Garcia-Sicilia J; Knuf M; Bernard L; Dieussaert I; Schuerman L
Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S77-88. PubMed ID: 19325450
[TBL] [Abstract][Full Text] [Related]
6. Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents.
Keyserling H; Papa T; Koranyi K; Ryall R; Bassily E; Bybel MJ; Sullivan K; Gilmet G; Reinhardt A
Arch Pediatr Adolesc Med; 2005 Oct; 159(10):907-13. PubMed ID: 16203934
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants.
Perrett KP; Snape MD; Ford KJ; John TM; Yu LM; Langley JM; McNeil S; Dull PM; Ceddia F; Anemona A; Halperin SA; Dobson S; Pollard AJ
Pediatr Infect Dis J; 2009 Mar; 28(3):186-93. PubMed ID: 19209097
[TBL] [Abstract][Full Text] [Related]
8. Expanding prevention of invasive meningococcal disease.
Pelton SI; Gilmet GP
Expert Rev Vaccines; 2009 Jun; 8(6):717-27. PubMed ID: 19485753
[TBL] [Abstract][Full Text] [Related]
9. Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents.
Jackson LA; Baxter R; Reisinger K; Karsten A; Shah J; Bedell L; Dull PM;
Clin Infect Dis; 2009 Jul; 49(1):e1-10. PubMed ID: 19476428
[TBL] [Abstract][Full Text] [Related]
10. [Bacterial meningitis caused by Neisseria meningitidis. Prophylactic measures].
Magdzik W
Przegl Epidemiol; 2004; 58(2):241-51. PubMed ID: 15521103
[TBL] [Abstract][Full Text] [Related]
11. Quadrivalent meningococcal ACYW-135 glycoconjugate vaccine for broader protection from infancy.
Pace D
Expert Rev Vaccines; 2009 May; 8(5):529-42. PubMed ID: 19397410
[TBL] [Abstract][Full Text] [Related]
12. Infant immunisation with a pneumococcal conjugate vaccine: from the age of two months, for all infants.
Prescrire Int; 2006 Dec; 15(86):227-33. PubMed ID: 17167934
[TBL] [Abstract][Full Text] [Related]
13. Update on the use of meningococcal serogroup C CRM₁₉₇-conjugate vaccine (Meningitec) against meningitis.
Badahdah AM; Rashid H; Khatami A
Expert Rev Vaccines; 2016; 15(1):9-29. PubMed ID: 26560735
[TBL] [Abstract][Full Text] [Related]
14. Prevention of meningococcal disease.
Kimmel SR
Am Fam Physician; 2005 Nov; 72(10):2049-56. PubMed ID: 16342836
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and reactogenicity of a three-dose primary vaccination course with a combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-haemophilus influenzae type b vaccine coadministered with a meningococcal C conjugate vaccine.
Tejedor JC; Omeñaca F; García-Sicilia J; Verdaguer J; Van Esso D; Esporrín C; Molina V; Muro M; Marés J; Enrubia M; Moraga F; García-Corbeira P; Dobbelaere K; Schuerman L;
Pediatr Infect Dis J; 2004 Dec; 23(12):1109-15. PubMed ID: 15626947
[TBL] [Abstract][Full Text] [Related]
16. Meningococcal disease: a review on available vaccines and vaccines in development.
Bröker M; Fantoni S
Minerva Med; 2007 Oct; 98(5):575-89. PubMed ID: 18043565
[TBL] [Abstract][Full Text] [Related]
17. Investigation of serum bactericidal activity in childhood and adolescence 3-6 years after vaccination with a single dose of serogroup C meningococcal conjugate vaccine.
Sakou II; Tzanakaki G; Tsolia MN; Sioumala M; Barbouni A; Kyprianou M; Papaevangelou V; Tsitsika A; Blackwell CC; Kafetzis D; Kremastinou J
Vaccine; 2009 Jul; 27(33):4408-11. PubMed ID: 19500554
[TBL] [Abstract][Full Text] [Related]
18. Menjugate (Chiron).
Jones DH
Curr Opin Investig Drugs; 2001 Jan; 2(1):47-9. PubMed ID: 11527011
[TBL] [Abstract][Full Text] [Related]
19. Fast tracking the vaccine licensure process to control an epidemic of serogroup B meningococcal disease in New Zealand.
Lennon D; Jackson C; Wong S; Horsfall M; Stewart J; Reid S
Clin Infect Dis; 2009 Aug; 49(4):597-605. PubMed ID: 19622040
[TBL] [Abstract][Full Text] [Related]
20. Vaccinating adolescents against meningococcal disease in Canada: a cost-effectiveness analysis.
De Wals P; Coudeville L; Trottier P; Chevat C; Erickson LJ; Nguyen VH
Vaccine; 2007 Jul; 25(29):5433-40. PubMed ID: 17560695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
